Skip to main content

Advertisement

Archived Comments for: s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal

Back to article

  1. Pre-Metabolic and Metabolic Syndrome are based on Inherited Mitochondrial Cytopathy.

    Sergio Stagnaro, Quantum Biophysical Semeiotics Research Laboratory

    4 October 2008

    Sirs,

    I find this paper really interesting and useful in preventing rather than recognizing metabolic syndrome. However, in Primary Prevention as well as early bedside diagnosis of Metabolic Syndrome, physicians have at the best to know Biophysical-Semeiotic Constitutions, fundamental ground of Single Patient Based Medicine, which fortunately completes EBM! (1, 2).

    Really, these constitutions exist and are based on inherited mitochondrial functional cytopathy, I discovered and described - for the first time - about 30 years ago, and termed as Congenital Acidosic Enzyme Metabolic Histangiopathy (1-15).

    Notoriously, Metabolic Syndrome (i.e., all its components) is preceded by the related biophysical-semeiotic constitutions, their corresponding inherited Real Risk, and then by Biophysical Semeiotic Pre-Metabolic Syndrome (See www.semeioticabiofisica.it and the linked Microangiologia) (2-4).

    Generally, the metabolic syndrome is characterized by a group of "so-called" metabolic risk factors in one person:

    A) Abdominal obesity (excessive fat tissue in and around the abdomen);

    B) Atherogenic dyslipidemia (blood fat disorders - high triglycerides, low

    HDL cholesterol and high LDL cholesterol - that foster plaque buildups in artery walls);

    C) Elevated blood pressure;

    D) Insulin resistance or glucose intolerance (the body can't properly use

    insulin or blood sugar);

    E) Prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor-1 in the blood) Proinflammatory state (e.g., elevated C-reactive protein in the blood).

    As I referred previously, also recently (15), all these components of Metabolic Syndrome may occur exclusively in individuals involved by Congenital Acidosic Enzyme Metabolic Histangiopathy as well as by either "some" or all biophysical-semeiotic constitutions.

    In a few words, not all patients with Metabolic Syndrome are equal!

    Interestingly, such as important data, gathered bedside with the aid of Biophysical Semeiotics, since last November Quantum Biophysical Semeiotics, proved to be reliable in my long well-established clinical experience.

    In fact, they highlight intriguing aspects of metabolic syndrome, until now unexplained: for instance, only 50% of this syndrome is associated with impairment of glucose metabolism, e.g., type 2 diabetes! In fact, no one authors all around the world has been able to give full explanation about what accounts for the reason that glucose metabolism is altered only in an half of patients with Metabolic Syndrome. In addition, CAD primary prevention have to be performed exclusively in those patients involved by CAD inherited Real Risk, based on coronary micorcirculatory remodelling, wherein newborn-pathological, type I, subtype b), aspecific, Endoarteriolar Blocking Devices play a central role (8, 9, 17)

    References

    1) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico-

    Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la

    definizione della Single Patient Based Medicine. Travel Factory, Roma,

    2004. http://www.travelfactory.it

    2) Stagnaro S., Stagnaro-Neri M., Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Ed. Travel Factory, Roma, 2005

    3) Stagnaro SergioBiophysical Semeiotic Constitutions, Genomics, and

    Cardio-Vascular Diseases. BMC Cardiovascular Disorders

    http://www.biomedcentral.com/1471-2261/4/20/comments#95454 2004

    4) Stagnaro Sergio. Single Patient Based Medicine: its paramount role in

    Future Medicine. Public Library of Science.

    http://medicine.plosjournals.org/perlserv/?request=read-response 2005

    5) Stagnaro Sergio. Bedside diagnosing diabetic and dyslipidaemic

    constitutions and diabetes real risk. 2 October 2006, Brit. Col. Med.

    Journal. http://www.cmaj.ca/cgi/eletters/175/7/733 2006

    6) Stagnaro Sergio. Hypertensive Constitution accounts for the existence

    of diabetics with and without Hypertension. Cardiovascular Diabetology

    2006, 5:19 doi:10.1186/1475-2840-5-19 2006

    7) Stagnaro Sergio. Biophysical-Semeiotic Diabetic "and" Dyslipidaemic

    Constitutions and Primary Prevention. Annals of Family Medicine

    http://www.annfammed.org/cgi/eletters/4/5/427 2006

    8) Stagnaro Sergio. Newborn-pathological Endoarteriolar Blocking Devices

    in Diabetic and Dislipidaemic Constitution and Diabetes Primary

    Prevention. The Lancet. March 06 2007

    http://www.thelancet.com/journals/lancet/article/PIIS0140673607603316/comments?action=view&totalComments=1

    9) Stagnaro Sergio. New bedside way in Reducing mortality in diabetic

    men and women. 21 June 2007. http://www.annals.org/cgi/eletters/0000605-200708070-00167v1

    10) Stagnaro Sergio. Teoria Patogenetica Unificata, 2006, Ed. Travel Factory, Roma. 2006

    11) Stagnaro S. Pivotal role of Biophysical Semeiotic Constitutions in

    Primary Prevention. Cardiovascular Diabetology, 2:1,

    http://www.cardiab.com/content/2/1/13/comments#5753 2003

    12) Stagnaro Sergio. Bedside Recognizing CAD Inherited Real Risk and silent CAD with Biophysical Semeiotics. Lipid in Health and Disease. (29 May 2008) http://www.lipidworld.com/content/7/1/19/comments#299588

    13) Stagnaro Sergio. Alzheimer's Disease Byophysical Semeiotics supports the pathophysiology of Koudinov's theory.11 January 2002. Clin. Med. & Health Research http://clinmed.netprints.org/cgi/eletters/2001100005v1#9

    14) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica.

    Gazz Med. It. - Asch. Sci, Med. 144, 423, 1985.

    15) Stagnaro Sergio. Epidemiological evidence for the non-random

    clustering of the components of the metabolic syndrome: multicentre study

    of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr.

    2007 Feb 7; [PubMed]

    16) Stagnaro Sergio. Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning - c007i. Lecture, V Virtual International Congress of Cardiology. 2007 http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php

    17) Stagnaro Sergio. Renin-angiotensin blockade and kidney disease inherited real risk. The Lancet.com, September 23, 2008.

    http://www.thelancet.com/journals/lancet/article/PIIS014067360861212X/comments?action=view&totalComments=2#1841

    Competing interests

    None declared

  2. Paramount Inherited Functional Mitochondrial Cytopathy, Pre-Metabolic and Metabolic Syndrome are based on.

    Sergio Stagnaro, Quantum Biophysical Semeiotics Research Laboratory

    4 October 2008

    Sirs,

    this paper is really intriguing and interesting. However, in Primary Prevention as well as early bedside diagnosis of Metabolic Syndrome, physicians have necessarily to know Biophysical-Semeiotic Constitutions, fundamental ground of Single Patient Based Medicine, which fortunately completes EBM! (1, 2).

    Really, the constitutions exist and are based on inherited mitochondrial functional cytopathy, I discovered and described - for the first time - about 30 years ago, and termed as Congenital Acidosic Enzyme Metabolic Histangiopathy (1-15).

    Notoriously, Metabolic Syndrome (i.e., all its components) is preceded by the related biophysical-semeiotic constitutions, their corresponding inherited Real Risk, and then by Biophysical Semeiotic Pre-Metabolic Syndrome (See www.semeioticabiofisica.it and the linked Microangiologia) (2-4).

    Generally, the metabolic syndrome is characterized by a group of "so-called" metabolic risk factors in one person:

    A) Abdominal obesity (excessive fat tissue in and around the abdomen);

    B) Atherogenic dyslipidemia (blood fat disorders - high triglycerides, low

    HDL cholesterol and high LDL cholesterol - that foster plaque buildups in artery walls);

    C) Elevated blood pressure;

    D) Insulin resistance or glucose intolerance (the body can't properly use

    insulin or blood sugar);

    E) Prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor-1 in the blood) Proinflammatory state (e.g., elevated C-reactive protein in the blood).

    As I referred previously, also recently (15), all these components of Metabolic Syndrome may occur exclusively in individuals involved by Congenital Acidosic Enzyme Metabolic Histangiopathy as well as by either "some" or all biophysical-semeiotic constitutions.

    In a few words, not all patients with Metabolic Syndrome are equal!

    Interestingly, such as important data, gathered bedside with the aid of Biophysical Semeiotics, since last November Quantum Biophysical Semeiotics, proved to be reliable in my long well-established clinical experience.

    In fact, they highlight intriguing aspects of metabolic syndrome, until now unexplained: for instance, only 50% of this syndrome is associated with impairment of glucose metabolism, e.g., type 2 diabetes! In fact, no one authors all around the world has been able to give full explanation about what accounts for the reason that glucose metabolism is altered only in an half of patients with Metabolic Syndrome. In addition, CAD primary prevention have to be performed exclusively in those patients involved by CAD inherited Real Risk, based on coronary micorcirculatory remodelling, wherein newborn-pathological, type I, subtype b), aspecific, Endoarteriolar Blocking Devices play a central role (8, 9, 16)

    References

    1) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico-Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Travel Factory, Roma, 2004. http://www.travelfactory.it

    2) Stagnaro S., Stagnaro-Neri M., Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Ed. Travel Factory, Roma, 2005

    3) Stagnaro SergioBiophysical Semeiotic Constitutions, Genomics, and Cardio-Vascular Diseases. BMC Cardiovascular Disorders

    http://www.biomedcentral.com/1471-2261/4/20/comments#95454 2004

    4) Stagnaro Sergio. Single Patient Based Medicine: its paramount role in Future Medicine. Public Library of Science. http://medicine.plosjournals.org/perlserv/?request=read-response 2005

    5) Stagnaro Sergio. Bedside diagnosing diabetic and dyslipidaemic constitutions and diabetes real risk. 2 October 2006, Brit. Col. Med. Journal. http://www.cmaj.ca/cgi/eletters/175/7/733 2006

    6) Stagnaro Sergio. Hypertensive Constitution accounts for the existence

    of diabetics with and without Hypertension. Cardiovascular Diabetology

    2006, 5:19 http://www.cardiab.com/content/5/1/19/comments

    7) Stagnaro Sergio. Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr. 2007 Feb 7; [MEDLINE]

    8) Stagnaro Sergio. Newborn-pathological Endoarteriolar Blocking Devices

    in Diabetic and Dislipidaemic Constitution and Diabetes Primary

    Prevention. The Lancet. March 06 2007

    http://www.thelancet.com/journals/lancet/article/PIIS0140673607603316/comments?action=view&totalComments=1

    9) Stagnaro Sergio. New bedside way in Reducing mortality in diabetic

    men and women. 21 June 2007. http://www.annals.org/cgi/eletters/0000605-200708070-00167v1

    10) Stagnaro Sergio. Teoria Patogenetica Unificata, 2006, Ed. Travel Factory, Roma. 2006

    11) Stagnaro S. Pivotal role of Biophysical Semeiotic Constitutions in

    Primary Prevention. Cardiovascular Diabetology, 2:1,

    http://www.cardiab.com/content/2/1/13/comments#5753 2003

    12) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica

    condizione necessaria non sufficiente della oncogenesi. XI Congr. Naz.

    Soc. It. di Microangiologia e Microcircolaz. Abstracts, pg 38, 28

    Settembre-1 Ottobre, 1983, Bellagio.

    13) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica. X

    Congr. Naz. Soc. It. di Microangiologia e Microcircolazione. Atti, 61. 6-7

    Novembre, 1981. Siena.

    14) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica.

    Gazz Med. It. - Asch. Sci, Med. 144, 423, 1985.

    15) Stagnaro Sergio. Epidemiological evidence for the non-random

    clustering of the components of the metabolic syndrome: multicentre study

    of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr.

    2007 Feb 7; [PubMed]

    16) Stagnaro Sergio. Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning - c007i. Lecture, V Virtual International Congress of Cardiology. http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php

    Competing interests

    None declared

Advertisement